Loading...
  • tumors
  • Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. (hindawi.com)
  • Patients whose tumors contain small cell or sarcomatoid elements. (knowcancer.com)
  • 2 dose of dasatinib in pediatric patients with refractory solid tumors. (knowcancer.com)
  • An independent Data Monitoring Committee (DMC) recommended halting the trial after concluding that Sutent demonstrated greater progression-free survival compared to placebo plus best supportive care in patients with pancreatic islet cell tumors. (medicalnewstoday.com)
  • Drug
  • V. Correlate the Childs-Pugh classification of hepatic dysfunction with observed toxic effects, pharmacodynamics, and pharmacokinetics of this drug in these patients. (clinicaltrials.gov)
  • Correlate, preliminarily, CD117 and platelet-derived growth factor receptor expression levels with response in patients treated with this drug. (clinicaltrials.gov)
  • Correlate radiographic imaging and metabolic imaging with histological response in patients treated with this drug. (clinicaltrials.gov)
  • Characterize the pharmacokinetic behavior of this drug in this patient population. (knowcancer.com)
  • In February 2010, the US Food & Drug Administration (FDA) granted Tasigna priority review status for newly diagnosed Ph+ CML patients. (salesandmarketingnetwork.com)
  • locally advanced
  • Open-label trial in patients with locally advanced GISTs admitted to Department of Surgery, Beijing Cancer Hospital and Institute between April 2010 and May 2013 was carried out prospectively. (clinicaltrials.gov)
  • Bevacizumab
  • Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported in patients who received SUTENT as monotherapy and in combination with bevacizumab. (pfizerpro.com)